Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
AssigneeNestec S.A.
InventorsJacques Edouard Germond, Blaise Corthesy, Beat Mollet, Rodolphe Fritsche
Life of this patent
Estimating the term…
Abstract
The present invention pertains to novel strains of lactic acid bacteria that are capable to reduce an individual's tendency to mount allergic reactions. In particular, the present invention relates to the generation of lactic acid bacteria strains that express proteins including tolerogenic peptides and the use thereof in reducing an individual's tendency to mount allergic reactions. The invention also pertains to food or pharmaceutical compositions containing said micro-organisms or active fractions thereof.
Claims20
A bacterial strain of a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to said polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at the periphery of said polypeptide, wherein the peptide is T1.
A food composition comprising a bacterial strain of a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to said polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at a periphery of said polypeptide, or a supematant thereof, wherein the peptide is T1.
A composition comprising a bacterial strain of a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to said polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at a periphery of said polypeptide, or a supematant thereof, wherein the peptide is T1.
A method of making an ingestable carrier, the method comprising the step of adding to the ingestable carrier a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to said polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at a periphery of said polypeptide to produce the ingestable carrier, wherein the peptide is T1.
A method of making a food composition, the method comprising the step of providing a food composition and adding to the food composition a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at the periphery of said polypeptide to produce an ingestable carrier, wherein the peptide is T1.
A composition comprising a bacterial strain of a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at a periphery of said polypeptide, wherein the peptide is T1, and wherein a cell membrane fraction of lysed bacteria are utilized.
A method for the treatment of an allergy in an individual, the method comprising the steps of administering to the individual having the allergy a therapeutically-effective amount of a bacterial strain of a lactic acid bacterium group, expressing a polypeptide, said polypeptide comprising a tolerogenic peptide heterologous to said polypeptide, such that the peptide is stabilized towards degradation by stomach/duodenal enzymes, and retains its tolerogenic properties and is displayed at a periphery of said polypeptide, wherein the peptide is T1.
Dependencies are inferred from the claim text.